The Application of Gut Microbiota in the Diagnosis, Prognosis and Treatment of Colorectal Cancer
DOI:
https://doi.org/10.54097/d6f9xy38Keywords:
Gut microbiota; colorectal cancer; biomarker; fecal microbiota transplantation.Abstract
The gut microbiota plays a significant role in the occurrence and development of colorectal cancer (CRC), and its application value in the diagnosis and treatment of CRC has received extensive attention in recent years. The gut microbiota has shown great potential as a non-invasive biomarker and therapeutic target in CRC. However, existing reviews mostly focus on mechanism descriptions and lack systematic analysis of clinical translation barriers. This article focuses on CRC and systematically reviews the research progress of the microbiota as a diagnostic biomarker, prognostic biomarker, and therapeutic target, and emphasizes the discussion of translation barriers and solutions. In terms of diagnosis, fecal microbiota testing faces the lack of standardization and interference from confounding factors. About prognosis, the unclear causal relationship and insufficient standardization of bioinformatics limit clinical application. In terms of treatment, fecal microbiota transplantation and probiotics and other intervention strategies are limited by individual variability, regulatory barriers, and insufficient strain specificity. This article proposes three major solution paths: standardization construction, multi-omics integration, and precise intervention, providing a reference for the clinical translation of microbiota research results.
Downloads
References
[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2024, 74(3): 229-263.
[2] LIN J S, PERDUE L A, HENRIKSON N B, et al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force[J]. JAMA, 2021, 325(19): 1978.
[3] A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche - PMC[EB/OL]. [2026-04-01]. https://pmc.ncbi.nlm.nih.gov/articles/PMC11006615/.
[4] LIU N N, JIAO N, TAN J C, et al. Multi-kingdom microbiota analyses identifybacterial–fungal interactions and biomarkers of colorectal cancer acrosscohorts[J]. Nature Microbiology, 2022, 7(2): 238-250.
[5] PNG C W, CHUA Y K, LAW J H, et al. Alterations in co-abundant bacteriome in colorectal cancer and its persistence after surgery: a pilot study[J]. Scientific Reports, 2022, 12(1): 9829.
[6] YAO Q, TANG M, ZENG L, et al. Potential of fecal microbiota for detection and postoperative surveillance of colorectal cancer[J]. BMC Microbiology, 2021, 21(1): 156.
[7] WANG J, CONG Y, TANG B, et al. Integrative analysis of multi-omics data and gut microbiota composition reveals prognostic subtypes and predicts immunotherapy response in colorectal cancer using machine learning[J]. Scientific Reports, 2025, 15: 25268.
[8] SU X, JIN J, HUANG Y, et al. Tumor-suppressing multi-enterobacteria enhance the anti-PD-1/PD-L1 efficacy in microsatellite stable colorectal cancer[J]. Scientific Reports, 2026.
[9] HUANG J, ZHENG X, KANG W, et al. Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer[J]. Frontiers in Immunology, 2022, 13: 874922.
[10] HU S, LUO C, WAN S, et al. Modulating the gut microbiome to enhance cancer immunotherapy: a systematic review and Meta-Analysis of probiotics and FMT as adjuncts[J]. BMC cancer, 2026, 26(1): 279.
[11] WU Y, JIAO N, ZHU R, et al. Identification of microbial markers across populations in early detection of colorectal cancer[J]. Nature Communications, 2021, 12: 3063.
[12] TSAI Y J, LYU W N, LIAO N S, et al. Gut microbiome-based machine learning model for early colorectal cancer and adenoma screening[J]. Gut Pathogens, 2025, 17(1): 80.
[13] HUH J W, KIM M J, KIM J, et al. Enterotypical Prevotella and three novel bacterial biomarkers in preoperative stool predict the clinical outcome of colorectal cancer[J]. Microbiome, 2022, 10(1): 203.
[14] MORALES M F G, HOGUE S R, PITCHER S, et al. Survival implications of the age-associated tumor and normal adjacent tissue microbiome among colorectal cancer patients[J]. Gut Pathogens, 2025, 17: 109.
[15] LO C H, WU D C, JAO S W, et al. Enrichment of Prevotella intermedia in human colorectal cancer and its additive effects with Fusobacterium nucleatum on the malignant transformation of colorectal adenomas[J]. Journal of Biomedical Science, 2022, 29: 88.
[16] ALEXANDER J L, POSMA J M, SCOTT A, et al. Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer[J]. Microbiome, 2023, 11(1): 100.
[17] XU S, KONG J, DAI Y, et al. Prevotellaceae Modulates Colorectal Cancer Immune Microenvironment to Assist Anti-PD-L1 Immunotherapy[J]. Turkish Journal of Gastroenterology, 2024, 35(12): 909-921.
[18] DAI C S, QI T T, SHANG H L, et al. Intratumoral microbiota-derived S1P sensitizes the combination therapy of capecitabine and PD-1 inhibitors[J]. iScience, 2025, 28(12): 114202.
[19] ZHAO W, LEI J, KE S, et al. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215) [J]. eClinicalMedicine, 2023, 66: 102315.
[20] MOWAT C, DHATT J, BHATTI I, et al. short chain fatty acids prime colorectal cancer cells to activate antitumor immunity[J]. Frontiers in Immunology, 2023, 14.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
